Last reviewed · How we verify
picosalax plus bisacodyl
Picosalax plus bisacodyl is a bowel preparation combination that uses osmotic laxatives and a stimulant laxative to cleanse the colon by drawing fluid into the intestines and promoting peristalsis.
Picosalax plus bisacodyl is a bowel preparation combination that uses osmotic laxatives and a stimulant laxative to cleanse the colon by drawing fluid into the intestines and promoting peristalsis. Used for Bowel cleansing prior to colonoscopy, Bowel cleansing prior to other gastrointestinal procedures.
At a glance
| Generic name | picosalax plus bisacodyl |
|---|---|
| Sponsor | Queen's University |
| Drug class | Bowel preparation agent / Laxative combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Picosalax is an osmotic laxative containing sodium picosulfate, magnesium oxide, and citric acid that draws water into the bowel lumen to soften stool and increase intestinal motility. Bisacodyl is a stimulant laxative that directly stimulates colonic muscle contractions. Together, they provide enhanced bowel cleansing through complementary mechanisms—osmotic fluid retention and direct muscular stimulation.
Approved indications
- Bowel cleansing prior to colonoscopy
- Bowel cleansing prior to other gastrointestinal procedures
Common side effects
- Nausea
- Abdominal discomfort
- Vomiting
- Dehydration
- Electrolyte imbalance
Key clinical trials
- Improving Bowel Preparation for the Colon Capsule (PHASE3)
- A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- picosalax plus bisacodyl CI brief — competitive landscape report
- picosalax plus bisacodyl updates RSS · CI watch RSS
- Queen's University portfolio CI